AI Article Synopsis
- Acquired reactive perforating collagenosis (ARPC) is a rare skin condition where collagen is expelled through the skin, and its underlying causes are not well understood, though RAGE (a receptor involved in inflammation) may play a role.* -
- The study analyzed skin biopsy samples from 41 ARPC patients and 11 healthy controls to assess RAGE expression using immunohistochemistry, finding that ARPC patients showed significantly higher RAGE levels in certain skin cells compared to healthy tissue.* -
- The findings suggest that RAGE overexpression in ARPC lesions occurs regardless of diabetes status, but the study's semi-quantitative evaluation of RAGE expression presents a limitation.*
Article Abstract
Background: Acquired reactive perforating collagenosis (ARPC) is a rare skin disorder characterized by transepidermal elimination of dermal collagen. There is little data regarding the pathogenesis of ARPC. The receptor for advanced glycation end products (RAGE) is a multiligand transmembrane receptor that plays an important role in inflammatory responses and may be involved in the pathogenesis of ARPC.
Aim: To explore the expression of RAGE in ARPC.
Methods: Paraffin-embedded punch biopsy specimens of 41 patients with ARPC and of 11 healthy controls with normal skin were obtained from the Department Of Pathology. Clinical data of all patients were reviewed from the medical files. All specimens were stained immunohistochemically with antibody to RAGE (Anti-RAGE). The intensity of RAGE expression was assessed semi-quantitatively on epidermal cells, microvascular endothelium, dermal fibroblasts and inflammatory cells and graded as 0 (no staining), 1 (weak), 2 (moderate) and 3 (strong). The patients were divided into diabetic and nondiabetic groups for analysis.
Results: RAGE expression in microvascular endothelium, inflammatory cells and fibroblasts of patients with ARPC was more intense than normal tissues of healthy participants (P values are 0.005, 0.017 and P > 0.05).
Limitations: Our method of assessment of RAGE expression was semi-quantitative.
Conclusion: We observed an overexpression of RAGE in lesional samples of patients with ARPC which was independent of the presence of diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijdvl.IJDVL_113_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report.
Front Immunol
July 2024
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Article Synopsis
- Acquired reactive perforating collagenosis (ARPC) is a challenging skin condition that doesn’t respond well to typical immunosuppressive treatments and negatively impacts patients' quality of life.
- An 81-year-old woman with chronic itching and ulcerated lesions was diagnosed with ARPC after showing poor response to standard medications, leading to the initiation of baricitinib therapy.
- The treatment resulted in gradual symptom improvement without any adverse reactions, indicating that baricitinib could be an effective maintenance therapy for ARPC.
A case report on acquired reactive perforating collagenosis.
Medicine (Baltimore)
July 2024
Department of Dermatology, The Second People's Hospital of Hefei, Hefei, Anhui, China.
Article Synopsis
- - Acquired reactive perforating collagenosis (ARPC) is a rare skin condition that is often misdiagnosed, but using noninvasive skin microscopy can enhance diagnostic accuracy.
- - Comprehensive patient evaluations are essential due to ARPC's link with systemic diseases, and treatment mostly focuses on alleviating symptoms with medications like pregabalin and prednisone.
- - This case report highlights that clinical dermoscopy aids in diagnosing ARPC effectively and that pregabalin capsules significantly help reduce itching symptoms.
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
Prostate
August 2024
Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA.
Background: Preclinical models recapitulating the metastatic phenotypes are essential for developing the next-generation therapies for metastatic prostate cancer (mPC). We aimed to establish a cohort of clinically relevant mPC models, particularly androgen receptor positive (AR) bone metastasis models, from LuCaP patient-derived xenografts (PDX) that reflect the heterogeneity and complexity of mPC.
Methods: PDX tumors were dissociated into single cells, modified to express luciferase, and were inoculated into NSG mice via intracardiac injection.
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Cancer Res Commun
November 2023
Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington.
Article Synopsis
- Castration-resistant prostate cancer (CRPC) includes various subtypes, notably androgen receptor-active prostate cancer (ARPC) and neuroendocrine prostate cancer (NEPC), which can exist simultaneously in patients, complicating treatment strategies.
- Current therapies lack effectiveness across these different CRPC subtypes, prompting research on a new combined treatment approach.
- The study found that fimepinostat, a dual inhibitor of histone deacetylase (HDAC) and PI3K/AKT, significantly inhibits tumor growth in both ARPC and NEPC models, showing better results when both pathways are targeted together rather than separately.
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Prostate
January 2024
Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA.
Article Synopsis
- Scientists are studying how to treat prostate cancer, especially when it's hard to treat (like in castration-resistant prostate cancer or CRPC).
- They've found that some cancers can ignore the usual treatments that work by blocking a protein called the androgen receptor, and they think another pathway called FGFR might be important in these cancers.
- Experiments showed that using FGFR blockers together with existing treatments can help suppress tumor growth, but the effectiveness can vary depending on the specific type of cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!